Life Sciences

The Right Chemistry

Life sciences and medical devices companies face a unique set of operational and financial challenges, from conducting clinical trials to bringing products to market to expanding operations—all within a complex regulatory environment. How do successful businesses overcome these hurdles? It starts with seeking out the right mix of industry-specific accounting, tax, and consulting expertise.

Our integrated service approach provides our clients with functional expertise, industry knowledge, and specialized services to help them overcome financial challenges and take advantage of valuable opportunities.

Who We Serve

Our Life Sciences & Medical Devices Practice serves organizations of all sizes—from large multinational companies and publicly traded middle-market corporations to private firms and start-ups. Our clients specialize in many areas, including:

  • Biotechnology
  • Diagnostics
  • Medical devices
  • Pharmaceuticals
  • Digital health

Life Sciences Guides

Insights


Webcast
The new lease accounting standard will directly affect how technology and life sciences companies operate—potentially changing lease classifications and impacting compliance and performance ratios. Implementing the standard, which goes into effect for public business entities on December 15, 2018, and on December 15, 2019, for all other entities, will require significant time and energy. Join us for a webcast addressing what the new standard could mean for your business.

Article
Adequately preparing for due diligence can help position your company for better negotiations, higher valuations, and stronger outcomes.

Article
New lease accounting rules go into effect at the end of 2018. Learn about a three-pronged approach to preparing for their adoption.

Webcast
Every technology and life science company will potentially be affected by the new revenue recognition requirements of the Financial Accounting Standards Board’s Accounting Standards Codification® Topic 606. Please join us to learn how the new standard will potentially impact your company.

Alert
President Trump signs federal funding bill that suspends the medical device excise tax until January 2020.

Alert
Tax reform will have significant 2017 income tax implications for technology, life sciences, and communications and media companies.

National Practice Leader

Industry Professionals